Research programme: NF-kappa B inhibitors - Othera PharmaceuticalsAlternative Names: OT 300 programme - Othera Pharmaceuticals; OT-304
Latest Information Update: 12 Dec 2012
At a glance
- Originator Othera Pharmaceuticals
- Class Small molecules
- Mechanism of Action NF-kappa B inhibitors; Thromboplastin inhibitors; Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Thrombosis
- Discontinued Rheumatoid arthritis